WATCH; turnaround not established
Q2 sequential improvement but YoY decline and negative CFO
Watch: Require sustained demand and cash
Home / Research / Syngene International
WATCH; turnaround not established
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Q2 sequential improvement but YoY decline and negative CFO
Watch: Require sustained demand and cash
Still 8.6% below prior Q2
Watch: Compare H2
Recovery remains incomplete
Watch: Track cumulative sales
Rounded issuer management mix
Watch: Track both engines
16 November 2026 | NSE SYNGENE | Reference ₹441.20, Sage PRO EOD fallback
WATCH — turnaround rather than established growth. Syngene's strategically valuable integrated discovery and manufacturing platform has entered a period of restructuring, customer replacement and investment commercialisation. Q2 FY27 represents a genuine sequential improvement: revenue ₹832.7 crore versus ₹736.0 crore in June, operating EBITDA ₹147.4 crore versus ₹90.8 crore, and PAT ₹32.2 crore versus a ₹9.0 crore loss. However, revenue is still down 8.6% YoY, statutory profit down 52%, and H1 operating cash flow negative ₹143.2 crore. The question for an investor is not whether the global outsourcing sector will grow but whether Syngene can regain customer demand, convert capacity into commercial production, and earn sufficient returns on the capital it already deployed.
Syngene offers research, development and manufacturing of small and large molecules for pharmaceutical, biotechnology and adjacent scientific customers. The issuer's October presentation identifies 5,700+ scientists among 8,300+ employees across Bengaluru, Mangaluru, Hyderabad and Baltimore. These capabilities provide a platform to support projects from discovery to clinical development and manufacturing. Knowledge continuity can make transfer faster and improve process consistency. The customer nevertheless retains ownership of the drug programme, clinical decisions, approval risk and supply allocation. Integrated capability should not be interpreted as exclusive rights to every stage.
Management described discovery as about 65% of Q2 revenue, implying roughly ₹541 crore on rounded reported mix. Revenue declined both YoY and QoQ due to customer attrition earlier in H1. Demand for low-value FTE work faces competition from Chinese and emerging Indian CROs and cuts in some customer R&D budgets. The strategic reset aims for integrated higher-value services rather than purely competing on price per scientific FTE. Traditional FTE economics are driven by rates, billable headcount and utilisation; fee-for-service economics depend more on scope, output, productivity, pricing and delivery risk. This transition can improve differentiation but takes time and may create revenue volatility or contractual risk if efficiency and demand do not match expectations.
Key takeaways
CDMO was approximately 35% of Q2 revenue, around ₹291 crore on rounded mix. Management stated there was no Zoetis revenue during Q2, against prior-year Librela supplies, and growth elsewhere in CDMO offset part of the gap. The lost product was high margin. Consolidated weakness is a combination of legacy manufacturing loss and discovery attrition, not a single customer story. A new clinical development contract may contribute valuable revenue but does not necessarily replace a mature commercial contract's utilisation or margin. Underwrite a sequence of development milestones, filing batches, approval, commercial orders and repeat sales. Judge the manufacturing recovery on contribution and cash as well as gross order announcements.
Bengaluru Unit III secured additional contracts, including clinical materials for an existing partner. Multiple customers are at development, clinical or filing-batch stages. A technically complex siRNA/oligonucleotide manufacturing programme was completed.
This shows process-development and scale-up ability; neither the revenue nor recurring commercial demand from that programme was disclosed. Large-molecule and advanced-modality work has attractive potential differentiation but more demanding quality systems, specialised equipment, validation and regulatory execution.
Clinical failure, slower launch and customer allocation can all interrupt expected growth.
The first Bayview agreement with a large pharmaceutical customer supports the strategic rationale of a dual-continent delivery model. Management expects process development in India during FY27, tech transfer and drug-substance manufacturing in FY28. The product is not yet approved; future commercial supplies are contingent on approvals. Management acknowledged facility gaps to be addressed before full utilisation and did not disclose contract size or peak utilisation. The investment committee should distinguish signed business from mature commercial production. Track India development, transfer, validated batches, regulatory approval and actual recurring supply. This is a long-duration option on a diversified biologics business rather than a near-term revenue bridge.
Figures in INR crore except EPS; original consolidated financial results in INR million converted by dividing by 10. Q2/H1 unaudited and limited-reviewed; FY26 audited. Management operating EBITDA is rounded, while the table uses a consistent statutory derivation.
| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 | H1 FY27 | H1 FY26 | FY26 |
|---|---|---|---|---|---|---|
| Operating revenue | 832.7 | 736.0 | 910.6 | 1568.7 | 1785.1 | 3738.7 |
| Other income | 28.0 | 25.3 | 15.4 | 53.3 | 33.1 | 70.7 |
| Materials + inventory changes | 198.6 | 173.4 | 238.5 | 372.0 | 456.1 | 918.6 |
| Employee expense | 272.7 | 271.1 | 285.5 | 543.8 | 556.7 | 1149.0 |
| Other expense | 152.6 | 150.6 | 175.3 | 303.2 | 349.8 | 691.7 |
| Net forex loss | 61.4 | 50.1 | 11.8 | 111.5 | 16.6 | 60.9 |
| Derived operating EBITDA | 147.4 | 90.8 | 199.5 | 238.2 | 405.9 | 918.5 |
| D&A | 111.7 | 112.2 | 116.5 | 223.9 | 227.7 | 452.9 |
| Finance cost | 10.0 | 9.6 | 13.2 | 19.6 | 24.8 | 48.8 |
| PBT before exceptions | 53.7 | -5.7 | 85.2 | 48.0 | 186.5 | 487.5 |
| Exceptional charges | 6.7 | 13.5 | 0.0 | 20.2 | 0.0 | 76.6 |
| PBT after exceptions | 47.0 | -19.2 | 85.2 | 27.8 | 186.5 | 410.9 |
| Tax | 14.8 | -10.2 | 18.1 | 4.6 | 32.7 | 94.2 |
| PAT | 32.2 | -9.0 | 67.1 | 23.2 | 153.8 | 316.7 |
| Basic EPS, Rs | 0.80 | -0.22 | 1.67 | 0.58 | 3.82 | 7.87 |
Key takeaways
The issuer's rounded operating EBITDA ₹147 and adjusted PAT ₹38 reconcile to these statutory measures; adjusted PAT excludes net-of-tax employee termination benefits. H1 adjusted PAT ₹39 versus statutory ₹23.2. Do not mix adjusted EBITDA or PAT with statutory earnings or treat OCI as operating income.
Q2 sales rose ₹96.7 crore sequentially, while EBITDA rose ₹56.6 crore. Materials plus inventory increased ₹25.2 crore, employee expense ₹1.6 crore, other expenses ₹2.0 crore, forex loss ₹11.3 crore. Incremental reported EBITDA margin ~58.5%, an indication of cost absorption on recovering revenue rather than a repeatable long-run margin. Year on year sales declined ₹77.9 crore, materials/inventory fell ₹39.9 crore, employee cost fell ₹12.8 crore and other expenses fell ₹22.7 crore. Before forex, operating EBITDA was ₹208.8 crore versus ₹211.3 crore, nearly flat despite the sales decline. Forex loss increased ₹49.6 crore, explaining much of the reported EBITDA decline of ₹52.1 crore. The cost response is encouraging, but demand recovery is still essential.
Reported margin 17.7% in Q2 versus 12.3% Q1 and 21.9% Q2 FY26. Removing the entire statutory forex loss consistently gives 25.1%, 19.1% and 23.2%. The issuer describes a mid-20s Q2 margin adjusted for hedge loss and maintains mid-20s guidance before forex effects.
Management expects similar hedge losses in H2 owing to forward contracts on a dedicated customer through FY28. Thus ex-FX guidance should not be interpreted as a 25% reported margin. On ₹832.7 crore sales, ₹61.4 crore loss reduces margin by about 7.4 percentage points.
Forecast reported earnings explicitly; the hedge effect cannot simply be removed without modelling the contract and currency economics.
H1 revenue declined 12.1%, operating EBITDA declined 41.3%, PAT declined 84.9%. H1 ex-FX EBITDA ₹349.7 crore vs ₹422.5 crore, down 17.2%; margins 22.3% vs 23.7%. The deterioration is not purely currency accounting.
FY26 operating EBITDA ₹918.5 crore, 24.6% margin (26.2% ex forex), and PAT ₹316.7 crore include ₹76.6 crore exceptional charges. H1 depreciation ₹223.9 crore has remained substantial despite lower revenue.
Other income increased to ₹53.3 crore from ₹33.1 crore, partly supporting reported profit; it should not be counted as a core manufacturing margin.
H1 operating cash flow after tax negative ₹143.2 crore vs negative ₹45.1 crore. Operating profit before working-capital changes ₹216.2 crore vs ₹453.3 crore. Receivables released ₹116.9 crore, inventories consumed ₹26.5 crore, other financial/nonfinancial assets consumed ₹15.1 crore and grouped movements in trade payables, provisions and financial/other liabilities consumed ₹382.2 crore. Taxes paid net ₹52.5 crore. The grouped liability cash outflow is substantial; do not attribute all to one customer advance without detailed notes. Other current liabilities decreased ₹780.8 to ₹467.4 crore, reinforcing the importance of analysing advances and accruals. Receivable improvement was insufficient to prevent negative CFO.
Key takeaways
Management capital investment of around ₹200 crore is a different basis; do not subtract both. Overall investing cash flow positive ₹49.7 crore includes investment sales and deposit maturity; it is not operating cash. Financing cash flow negative ₹20.3 crore included ₹57.8 crore short-term net borrowing, ₹50.5 crore dividends and ₹27.5 crore lease payments. Cash fell from ₹228.6 to ₹119.9 crore after exchange effects. Liquid investments provide flexibility but cannot substitute indefinitely for operating cash.
September assets ₹6,658.5 crore vs ₹7,040.2 crore March; equity ₹4,858.8 vs ₹4,839.1 crore. PPE ₹2,447.5 vs ₹2,545.4 crore; CWIP ₹1,140.6 vs ₹1,040.4 crore; ROU assets ₹363.9 vs ₹384.5 crore. PPE plus CWIP ₹3,588.1 crore is almost flat, but more remains unfinished: CWIP share 31.8% versus 29.0%. Construction cost is not qualified productive capacity. Track commissioning, qualification, customer utilisation and incremental contribution. Revenue and profit must eventually grow on this asset base.
Current borrowing ₹67.2 crore vs ₹9.4 crore March; leases ₹440.2 crore. Cash less borrowing ₹52.7 crore; including leases, narrow net debt ₹387.5 crore before investments. Management net cash ₹1,392 crore is broader and needs unrestricted-asset reconciliation. Current ratio 1.65x vs 1.42x; lower liabilities can also consume cash.
Management disclosed roughly ₹66 crore of H1 Bayview pre-operating expenses capitalised in the call, and said capitalisation continues until first regulatory approval, best case H2 CY2028. Capitalisation does not make costs economically free: cash is spent and asset value increases, with eventual expense/depreciation recognition. If regulatory readiness or commercial supply takes longer, the invested-capital return may disappoint even if EBITDA initially appears protected. Verify policy, capitalised cost, qualification timeline and when expenses/depreciation begin. The first manufacturing agreement is encouraging but does not guarantee full utilisation or immediate cash.
Illustrative capital hurdle: on each ₹1,000 crore incremental productive capital, 15% post-tax return requires ₹150 crore NOPAT or ₹200 crore EBIT at 25% tax. With ₹80–100 crore incremental D&A, EBITDA ₹280–300 crore implies roughly ₹933–1,000 crore annual sales at 30% margin.
This is not Bayview's disclosed cost or forecast; it demonstrates why facility scale must be supported by cash-generating demand. FY26 operating EBIT ₹465.6 crore relative to September PPE/CWIP ₹3,588.1 crore suggests a rough 13% pre-tax asset return proxy.
H1 annualised operating EBIT ₹28.6 crore gives 0.8%. These are not full ROCE because average capital, leases, working capital, intangibles and treasury differ; they illustrate current weak absorption.
Management describes FY27 as a transition year focused on commercial execution, operating performance and a leaner cost base. Discovery repositioning and CDMO growth are complementary rather than mutually exclusive: a differentiated research platform can generate future development opportunities, while commercial production provides repeat scale. Management acknowledges that Q2 is early evidence, not a sustained recovery. Discovery client base stable in Q2 after prior attrition, yet revenue declined. Customer count is an imperfect indicator: smaller project scope, pricing and timing can reduce revenue even if retention improves. Follow new projects, customer revenue retention, programme progression and actual CRO sales.
Key takeaways
This is not Q3 guidance. It shows how hedge losses and depreciation can leave earnings far below historic peaks despite apparent operating margin improvement.
FY26 H2 revenue was ₹1,953.6 crore; H1 FY27 ₹1,568.7 crore. Flat FY27 annual sales require H2 ₹2,170 crore, +11.1% YoY and +38.3% vs H1. A 5% full-year decline requires H2 ₹1,983.1 crore, +1.5% YoY. Simply repeating Q2 ₹832.7 twice implies annual sales ₹3,234.1 crore, down 13.5%.
This bridge is more informative than sequential growth alone. Recalculate after Q3. Demand restoration, customer replacement and cost absorption must sustain a stronger second half before the FY28 case is underwritten.
Reference ₹441.20, 40.37 crore shares, equity value ~₹17,811 crore. FY26 EPS ₹7.87 implies 56.1x historical earnings. Narrow EV = equity value + ₹67.2 borrowings − ₹119.9 cash = ~₹17,758 crore, excluding leases and other financial assets; FY26 operating EBITDA ₹918.5 crore gives 19.3x. This is not a fully comparable EV without reconciliation of leases, unrestricted investments and cash; no live peer-multiple claim. Current H1 annualised EPS is unusually depressed. The recovery valuation must be based on an explicit future earnings bridge.
Key takeaways
| FY28 assumption | Bear | Base | Bull |
|---|---|---|---|
| Operating sales, ₹cr | 3500 | 4200 | 4800 |
| Ex-FX EBITDA margin | 21% | 26% | 30% |
| Ex-FX EBITDA | 735 | 1092 | 1440 |
| Forex loss | 180 | 150 | 100 |
| Operating EBITDA after FX | 555 | 942 | 1340 |
| Other income | 70 | 80 | 85 |
| D&A | 470 | 500 | 520 |
| Finance cost | 45 | 45 | 45 |
| PBT | 110 | 477 | 860 |
| PAT | 82.5 | 357.75 | 645 |
| EPS | 2.04 | 8.83 | 15.93 |
| Assumed terminal P/E | 35x | 45x | 55x |
| Indicative price, Rs | 71 | 397 | 876 |
| Change vs reference | -84% | -10% | +99% |
Reverse valuation: at 45x, ₹441.20 requires EPS ₹9.80, PAT ~₹397.1 crore on 40.5 crore shares. At 25% tax PBT ₹529.5 crore. With base D&A ₹500 crore, finance ₹45 crore, other income ₹80 crore and FX loss ₹150 crore, ex-FX EBITDA required ~₹1,144.5 crore.
At 26% margin sales ~₹4,402 crore, 17.7% above FY26. A 20% return requires EPS ₹11.77 and PAT ~₹476.5 crore; ex-FX EBITDA ~₹1,250.3 crore and sales ~₹4,809 crore. At ₹240 crore FX loss versus ₹150 crore, revenue hurdle increases by ₹346 crore at 26%.
A ₹100 crore incremental revenue contribution at 26% margin, unchanged fixed costs, 25% tax, yields ₹19.5 crore PAT, ~₹0.48 EPS or ₹21.7/share at 45x. Additional depreciation, financing and costs would reduce it.
Risk register: discovery attrition/price competition; delayed replacement of the high-margin Zoetis-related business; qualification, validation and commercial approvals at Unit III/Bayview; FX hedge impact through FY28; negative operating cash and liability/advance outflows; asset underutilisation and rising capitalised pre-operating costs; quality/compliance and clinical failure; leadership and execution transition; valuation compression if earnings recover less than expected. These risks can interact: delayed customer orders lower revenue, utilisation, cash, and valuation. A diversified CDMO portfolio can share global biotech spending and regulatory exposures.
Key takeaways
Source ledger. S1. Syngene statutory Q2/H1 results dated 27 October 2026, consolidated P&L, assets/liabilities, cash flow, notes and limited-review reports: https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026193349_OutcomeQ2FY27_Signed.pdf.
Original consolidated pages visually inspected; numbers in Rs million converted to crore. S2. Issuer investor presentation 27 October: https://www.bseindia.com/xml-data/corpfiling/AttachLive/7cbfce30-eefd-4576-930e-7da45d58b28c.pdf.
Canonical 56679, current semantic ACCEPT and scored. Operating highlights, mix, footprint and adjusted margin definitions. S3. Accepted Q2 call reproduction, canonical 93844, available 30 October:
Third-party reproduction of issuer remarks, not original issuer-hosted file. Used for hedge guidance, commercial timings, costs, discovery reset and CFO transition; key statements cross-checked to the deck.
S4. Issuer Q2 press release exchange filing 27 October: https://nsearchives.nseindia.com/corporate/SYNGENE2_27102026203515_PRQ2FY2027_Signed.pdf. S5. Q1 deck canonical 11920: https://www.bseindia.com/xml-data/corpfiling/AttachHis/dce7362f-915c-40a8-9bf6-9ac049615f53.pdf.
Q1 statutory comparison from S1. S6. Sage PRO quote ₹441.20 on 16 November, EOD fallback; refresh before acting.
Limitations: original issuer-hosted transcript parity, full independent institutional QA, verified live peer valuation, complete owner-cash DCF and facility-specific capital return reconciliation remain open. Analyst scenarios and monitoring thresholds are explicitly hypothetical. The publication is original source-verified research, not a certified full QA edition.
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
Issuer Q2 statutory results / presentation / analyst calculation
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.